The proportion of free PSA and upgrading of biopsy gleason score after radical prostatectomy

Urologia Internationalis

Volumn 84, Issue 4, 2010, Pages 378-381

  Visapää, Harri ^a   Hotakainen, Kristina ^a   Lundin, Johan ^a,b   Ala Opas, Martti ^a   Stenman, Ulf Hkan ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Gleason score; Prostate biopsy; Prostate cancer; Prostate specific antigen; Upgrading

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; BIOPSY; BLOOD; CANCER STAGING; CHI SQUARE DISTRIBUTION; FINLAND; IMMUNOLOGY; PATHOLOGY; PREDICTIVE VALUE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

BIOPSY; CHI-SQUARE DISTRIBUTION; FINLAND; HUMANS; LOGISTIC MODELS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 77953221235     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000296302     Document Type: Article

References (17)

1. Van den Bergh RCN, Roemeling S, Roobol MJ, Schröder FH, Bangma CH: Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol 2007; 52: 1560-1563.
2. Pinthus JH, Witkos M, Fleshner NE, Sweet J, Evans A, Jewett MA, Krahn M, Alibhai S, Trachtenberg J: Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 2006; 176: 979-984.
3. Gofrit ON, Zorn KC, Taxy JB, Lin S, Zagaja GP, Steinberg GD, Shalhav AL: Predicting the risk of patients with biopsy Gleason score to harbor a higher grade cancer. J Urol 2007; 178: 1925-1928.
4. Müntener M, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, Walsh PC, Partin AW, Nielsen ME: Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 2008; 53: 767-776.
5. Dong F, Jones JS, Stephenson AJ, Magi-Galluzzi C, Reuther AM, Klein EA: Prostate cancer volume at biopsy predicts clinically significant upgrading. J Urol 2008; 179: 896-900.
6. Chun FK, Briganti A, Shariat SF, Graefen M, Montorsi F, Erbersdobler A, Steuber T, Salonia A, Currlin E, Scattoni V, Friedrich MG, Schlomm T, Haese A, Michl U, Colombo R, Heinzer H, Valiquette L, Rigatti P, Roehrborn CG, Huland H, Karakiewicz PI: Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int 2006; 98: 329-334.
7. Capitanio U, Karakiewicz PI, Jeldres C, Briganti A, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F: The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. Int J Urol 2009; 16: 526-529.
8. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Loveland KG, Bray KR: Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000; 56: 255-260.
9. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT, Lange PH, Gasior GH, Parson RE, Loveland KG: Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate-specific antigen: a prospective multicenter clinical trial. J Urol 1999; 162: 1346-1351.
10. Finne P, Finne R, Auvinen A, Juusela H, Aro J, Määttänen L, Hakama M, Rannikko S, Tammela TL, Stenman U: Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000; 56: 418-422.
11. Karakiewicz PI, Hutterer GC: Predictive models and prostate cancer. Nat Clin Pract Urol 2008; 5: 82-92.
12. Finne P, Auvinen A, Määttänen L, Tammela TL, Ruutu M, Juusela H, Martikainen P, Hakama M, Stenman UH: Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of < 3.0 μg/liter. Eur Urol 2008; 54: 362-370.
13. Elabbady AA, Khedr MM: Free/total PSA ratio can help in the prediction of high Gleason score prostate cancer in men with total serum prostate-specific antigen of 3-10 ng/ml. Int Urol Nephrol 2006; 38: 553-557.
14. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD: Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180: 1964-1967.
15. Freedland SJ, Kane CJ, Amling CL, Aronson WJ, Terris MK, Presti JC Jr, SEARCH Database Study Group: Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 2007; 69: 495-499.
16. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, Shariat SF, Slawin KM, Ohori M: Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-1797.
17. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW: Updated nomogram to predict pathologic stage of prostate cancer given prostatespecific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-1101.